ISGlobal, Hospital Clínic-Universitat de Barcelona, E-08036 Barcelona, Catalonia, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.
Sci Transl Med. 2020 May 13;12(543). doi: 10.1126/scitranslmed.aay8924.
Identifying immune correlates of protection and mechanisms of immunity accelerates and streamlines the development of vaccines. RTS,S/AS01E, the most clinically advanced malaria vaccine, has moderate efficacy in African children. In contrast, immunization with sporozoites under antimalarial chemoprophylaxis (CPS immunization) can provide 100% sterile protection in naïve adults. We used systems biology approaches to identifying correlates of vaccine-induced immunity based on transcriptomes of peripheral blood mononuclear cells from individuals immunized with RTS,S/AS01E or chemoattenuated sporozoites stimulated with parasite antigens in vitro. Specifically, we used samples of individuals from two age cohorts and three African countries participating in an RTS,S/AS01E pediatric phase 3 trial and malaria-naïve individuals participating in a CPS trial. We identified both preimmunization and postimmunization transcriptomic signatures correlating with protection. Signatures were validated in independent children and infants from the RTS,S/AS01E phase 3 trial and individuals from an independent CPS trial with high accuracies (>70%). Transcription modules revealed interferon, NF-κB, Toll-like receptor (TLR), and monocyte-related signatures associated with protection. Preimmunization signatures suggest that priming the immune system before vaccination could potentially improve vaccine immunogenicity and efficacy. Last, signatures of protection could be useful to determine efficacy in clinical trials, accelerating vaccine candidate testing. Nevertheless, signatures should be tested more extensively across multiple cohorts and trials to demonstrate their universal predictive capacity.
鉴定免疫保护相关因素和免疫机制可以加速和简化疫苗的研发。RTS,S/AS01E 是最具临床进展的疟疾疫苗,在非洲儿童中具有中等疗效。相比之下,在抗疟药物预防(CPS 免疫)下接种疟原虫孢子可在无经验的成年人中提供 100%的无菌保护。我们使用系统生物学方法,根据接受 RTS,S/AS01E 免疫或用寄生虫抗原体外刺激的外周血单核细胞转录组,鉴定疫苗诱导免疫的相关因素。具体来说,我们使用了来自两个年龄组和三个非洲国家参与 RTS,S/AS01E 儿科 3 期试验以及参与 CPS 试验的疟原虫无经验个体的样本。我们确定了与保护相关的预免疫和后免疫转录组特征。这些特征在 RTS,S/AS01E 3 期试验中的独立儿童和婴儿以及独立 CPS 试验中的个体中得到了验证,准确率均超过 70%。转录模块揭示了与保护相关的干扰素、NF-κB、Toll 样受体(TLR)和单核细胞相关特征。预免疫特征表明,在接种疫苗前对免疫系统进行预刺激可能会提高疫苗的免疫原性和疗效。最后,保护特征可用于确定临床试验中的疗效,从而加速候选疫苗的测试。然而,这些特征需要在多个队列和试验中进行更广泛的测试,以证明其普遍的预测能力。